Business context and reporting period
Entity discrepancy: The request identifies CalciMedica, Inc., but the supplied Form 10-Q is for Graybug Vision, Inc. (Nasdaq: GRAY). The summary below reflects the filing provided, not a CalciMedica filing. It covers the quarter ended March 31, 2021; amounts are in U.S. dollars.
Graybug is a clinical-stage biopharmaceutical company developing sustained-release treatments for retinal and optic-nerve diseases. It had no approved products or product revenue and devoted substantially all resources to research and development. Its lead candidate, GB-102, is being developed for wet age-related macular degeneration (wet AMD); GB-401 is in development for glaucoma.
Financial performance and position
| Metric | Q1 2021 | Q1 2020 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $6.4 million | $6.1 million |
| General and administrative expense | $5.0 million | $1.7 million |
| Total operating expenses / operating loss | $11.5 million | $7.8 million |
| Net loss | $11.4 million | $7.8 million |
| Net loss per share, basic and diluted | $0.54 | $6.61 |
| Cash used in operating activities | $9.3 million | $10.7 million |
Gross margin and other revenue-based margins are not applicable because the company reported no revenue. Cash, cash equivalents and short-term investments totaled $85.7 million at March 31, 2021 ($10.6 million cash and equivalents; $75.1 million short-term investments), compared with $95.0 million at December 31, 2020. Current assets were $88.8 million and current liabilities $6.3 million. Total liabilities were $6.3 million; the filing reports no debt balance. Accumulated deficit was $144.8 million.
Cash and cash equivalents fell $22.8 million during the quarter. Investing activities used $13.7 million, principally reflecting net purchases of short-term investments, which are included in the company’s liquid resources. Financing activities provided $0.1 million from option exercises. The company said its existing cash, cash equivalents and investments were expected to fund planned operations and capital expenditures for more than 12 months from issuance of the statements, while also stating it would seek additional financing.
Material changes versus the prior comparable period
- Net loss increased 47% to $11.4 million. R&D expense rose 6%; G&A expense increased by $3.3 million, primarily due to higher personnel and stock-based compensation, public-company insurance and costs, and a write-off of equipment-purchase deposits.
- Q1 expenses included approximately $2.2 million associated with terminating equipment-vendor and contract-manufacturer commitments: $1.3 million of equipment deposits written off and $0.9 million of other commitments and cancellation fees. The company reported $561,000 of unpaid cancellation-related costs accrued at quarter-end.
- Cash used in operations was lower than in Q1 2020 despite the higher net loss, reflecting working-capital movements and noncash stock-based compensation.
- Per-share loss is not directly comparable: the weighted-average share count rose to 21.0 million from 1.4 million following the 2020 IPO and preferred-stock conversion. Q1 2020 common-stockholder loss also included $1.3 million of cumulative preferred dividends.
Outlook, management commentary, risks and contingencies
- In March 2021, Graybug decided not to proceed with the significant investment needed to initiate two GB-102 Phase 3 trials in late 2021. In May, after quarter-end, it reported its full Phase 2b analysis and said further GB-102 clinical trials would require partner funding. It is seeking a partner; without one, further GB-102 wet AMD development, as well as GB-102 for diabetic macular edema and GB-103 for diabetic retinopathy, was described as unlikely or on hold.
- Management expected R&D expense to increase modestly in 2021, based on further GB-102 reformulation and preclinical work and a planned GB-401 Phase 1 trial in the first half of 2022. These plans and timing are forward-looking and subject to change.
- The filing highlights clinical and regulatory uncertainty. It reports that in the Phase 2b trial only 48% of patients receiving GB-102 1 mg achieved six months without additional supportive therapy; average visual-acuity results were lower than in the Eylea control arm. Earlier safety concerns involving the 2 mg dose led the company to discontinue that dose.
- Funding remains a key risk: Graybug expects ongoing losses, has no committed credit facility, and may need equity, debt, collaboration or licensing proceeds. Financing may be unavailable or dilutive; failure to obtain funds could require delaying or reducing development programs.
- As of March 31, approximately $3.1 million of vendor and clinical-development commitments were due within three to 12 months. Future minimum operating lease payments totaled $1.07 million. No material legal proceedings or material indemnification claims were reported.
- Management said COVID-19 had not significantly affected operations to date, but noted potential risks to clinical monitoring, suppliers, staffing and trial timelines. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the intended issuer: the provided filing is Graybug Vision, Inc., not CalciMedica, Inc.
- Check the status and terms of any GB-102 development partnership and whether further clinical trials will proceed.
- Review the complete Phase 2b results, including efficacy, durability and safety, and the consequences for GB-102’s prospects.
- Monitor cash burn, financing activity and runway assumptions, which depend on the company’s revised development plans.
- Track GB-401’s planned Phase 1 timing and the continued hold on GB-102 for DME and GB-103 for diabetic retinopathy.